Understanding Sotatercept and PAH Treatment

Sotatercept (Winrevair; Merck) is‌ emerging​ as a ‍notable advancement in the treatment of pulmonary arterial hypertension ⁤(PAH), offering a new ‍approach‌ to improve long-term​ outcomes for ⁢patients. Vallerie McLaughlin, MD, Kim A. Eagle M.D.Endowed Professor of Cardiovascular⁢ Medicine and professor of internal medicine ​at the University of michigan Medical School, highlighted the benefits ⁤of sotatercept at the 2025 American heart ‍Association⁢ Scientific Sessions in New Orleans, Louisiana, November​ 7-10, ⁤2025.

Addressing‌ Limitations of Current PAH Therapies

Despite the availability of‌ multiple PAH⁢ therapies targeting‍ three different ⁢pathways, patients⁣ still experience significant‌ morbidity ⁢and mortality. Current treatments⁢ often involve combination regimens, but even ​with these approaches, outcomes remain suboptimal. Sotatercept offers a new ‌mechanism of action, ⁤demonstrating benefit‌ even ⁢in patients ‌already receiving‍ established therapies.

Dr. McLaughlin explained, “We⁣ are so ​fortunate to ⁤have so ​many therapies⁣ for​ PAH, and we ⁣use ⁤combination therapy⁢ all the time. We’ve had medicines from ‍3 different pathways for ‌decades, and even though ​we‌ use those medicines ​in‌ combination,⁣ we still lose ‌far to many patients to this disease. ⁤We now have⁢ many trials demonstrating the benefit⁢ of adding sotatercept, or winrevair, to that conventional⁢ therapy. In fact,​ the patients in these ​trials were very highly‍ pretreated with those other conventional therapies and‌ still experienced a benefit from the addition of sotatercept.”

Identifying Patients Most Likely to Benefit

Determining which⁣ patients will benefit most ⁢from⁢ sotatercept requires careful consideration of individual risk profiles⁣ and disease burden. While patients ⁢not achieving low-risk status‌ are ⁤clear candidates, Dr. McLaughlin emphasizes that sotatercept ⁤should also be considered for those‌ who‍ technically meet low-risk criteria⁣ but still exhibit significant right ventricular‍ (RV) dysfunction or a high disease burden.

“Certainly, patients who aren’t achieving low-risk [status] need‌ additional therapy, and we consider sotatercept in those patients.‍ But there are many patients who technically meet low-risk [status] but‌ still have a high burden of disease,still have bad RV [right ventricular] dysfunction that‍ we also ‌consider it in,” she stated.

The decision-making process is individualized, with clinicians constantly evaluating how to optimize long-term outcomes for each patient. ⁤ Dr. McLaughlin shared, “Every time‌ I see a patient, no‌ matter what the risk ‌category is, I think, ‘How ⁢can I optimize this patient’s long-term outcomes?’ And I’m often ⁣thinking about whether or not sotatercept is an ⁤appropriate therapy ​in that patient.”

Clinical Trial Data Supporting Sotatercept’s Use

The benefits of sotatercept are supported by ⁤data from the ⁢PULSAR, ⁤STELLAR, and ZENITH trials. A pooled ​analysis of these trials, presented at the AHA 2025⁢ Scientific Sessions, demonstrated significant improvements in‍ key clinical outcomes⁢ when sotatercept was⁢ added to background PAH therapy.